Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection
- PMID: 15793108
- PMCID: PMC1068632
- DOI: 10.1128/AAC.49.4.1337-1339.2005
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection
Abstract
The time that concentrations in serum are above the MIC (T>MIC) is the pharmacokinetic/pharmacodynamic parameter correlating with the therapeutic efficacy of beta-lactam antibiotics. The aim of this study was to demonstrate the T>MIC of meropenem when administered by a 3-h infusion compared with that when administered by bolus injection. The study was conducted with nine patients with ventilator-associated pneumonia. Each subject received meropenem in three regimens consecutively: (i) bolus injection of 1 g every 8 h for 24 h; (ii) 3-h infusion of 1 g every 8 h for 24 h; and (iii) 3-h infusion of 2 g every 8 h for 24 h. Following bolus injection, the percentages of the T>MICs of 16, 8, 4, and 1 microg/ml were 28.33% +/- 11.67%, 45.89% +/- 22.90%, 57.00% +/- 24.82%, and 74.67% +/- 17.94% of an 8-h interval, respectively. For the 3-h infusion of 1 g of meropenem, the percentages of the T>MICs of 16, 8, 4, and 1 microg/ml were 37.78% +/- 20.57%, 58.11% +/- 24.38%, 72.67% +/- 21.97%, and 93.56% +/- 6.84% of an 8-h interval, respectively. For the 3-h infusion of 2 g of meropenem, the percentages of the T>MICs of 16, 8, 4, and 1 microg/ml were 57.89% +/- 24.26%, 72.89% +/- 22.40%, 85.56% +/- 16.42%, and 98.56% +/- 3.28% of an 8-h interval, respectively. In conclusion, a 3-h infusion resulted in greater T>MICs than those after a bolus injection. For the treatment of infections caused by pathogens with intermediate resistance, a 3-h infusion of 2 g of meropenem every 8 h can provide concentrations in serum above the MIC of 16 microg/ml for almost 60% of an 8-h interval.
Figures
Similar articles
-
Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.J Med Assoc Thai. 2013 Oct;96(10):1283-9. J Med Assoc Thai. 2013. PMID: 24350408 Clinical Trial.
-
Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.Int J Antimicrob Agents. 2011 Sep;38(3):231-6. doi: 10.1016/j.ijantimicag.2011.04.019. Epub 2011 Jul 2. Int J Antimicrob Agents. 2011. PMID: 21726984 Clinical Trial.
-
Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.J Antimicrob Chemother. 2003 Sep;52(3):518-21. doi: 10.1093/jac/dkg378. Epub 2003 Aug 13. J Antimicrob Chemother. 2003. PMID: 12917242 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic properties of meropenem.Clin Infect Dis. 2008 Sep 15;47 Suppl 1:S32-40. doi: 10.1086/590064. Clin Infect Dis. 2008. PMID: 18713048 Review.
-
Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.Ann Pharmacother. 2010 Mar;44(3):557-64. doi: 10.1345/aph.1M339. Epub 2010 Feb 2. Ann Pharmacother. 2010. PMID: 20124468 Review.
Cited by
-
Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients.Infect Drug Resist. 2023 Jun 21;16:3989-3997. doi: 10.2147/IDR.S408572. eCollection 2023. Infect Drug Resist. 2023. PMID: 37366501 Free PMC article.
-
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review.Drugs. 2023 Jul;83(11):967-983. doi: 10.1007/s40265-023-01893-6. Epub 2023 Jun 14. Drugs. 2023. PMID: 37314633 Review.
-
The effectiveness of colistin/levofloxacin compared to colistin/meropenem in the treatment of ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial.Res Pharm Sci. 2022 Dec 24;18(1):39-48. doi: 10.4103/1735-5362.363594. eCollection 2023 Feb. Res Pharm Sci. 2022. PMID: 36846731 Free PMC article.
-
In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Klebsiella pneumoniae Clinical Isolates.Antibiotics (Basel). 2023 Jan 23;12(2):237. doi: 10.3390/antibiotics12020237. Antibiotics (Basel). 2023. PMID: 36830148 Free PMC article.
-
Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients.Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0084522. doi: 10.1128/aac.00845-22. Epub 2022 Oct 13. Antimicrob Agents Chemother. 2022. PMID: 36226944 Free PMC article.
References
-
- Cockcroft, D. W., and H. M. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. - PubMed
-
- Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96. - PubMed
-
- Craig, W. A. 1996. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 25:213-217. - PubMed
-
- Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
